These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 14639671)
61. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. Stephenson DT; Meglasson MD; Connell MA; Childs MA; Hajos-Korcsok E; Emborg ME J Pharmacol Exp Ther; 2005 Sep; 314(3):1257-66. PubMed ID: 15980058 [TBL] [Abstract][Full Text] [Related]
62. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484 [TBL] [Abstract][Full Text] [Related]
63. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]
65. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115 [TBL] [Abstract][Full Text] [Related]
66. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428 [TBL] [Abstract][Full Text] [Related]
67. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492 [TBL] [Abstract][Full Text] [Related]
69. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
70. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739 [TBL] [Abstract][Full Text] [Related]
71. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Bezard E; Hill MP; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H Eur J Pharmacol; 2004 Feb; 485(1-3):159-64. PubMed ID: 14757136 [TBL] [Abstract][Full Text] [Related]
73. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Henry B; Fox SH; Crossman AR; Brotchie JM Exp Neurol; 2001 Sep; 171(1):139-46. PubMed ID: 11520128 [TBL] [Abstract][Full Text] [Related]
74. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306 [TBL] [Abstract][Full Text] [Related]
75. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687 [TBL] [Abstract][Full Text] [Related]